Celularity Inc. (NASDAQ:CELU) Short Interest Up 67.4% in February

Celularity Inc. (NASDAQ:CELU) was the recipient of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 287,400 shares, an increase of 67.4% from the January 31st total of 171,700 shares. Based on an average trading volume of 167,600 shares, the days-to-cover ratio is currently 1.7 days. Currently, 2.6% of the company’s shares are sold short.

Celularity Price Performance

Shares of CELU stock traded down $0.11 on Tuesday, hitting $1.06. 217,110 shares of the company’s stock traded hands, compared to its average volume of 158,317. The company’s fifty day simple moving average is $2.07 and its 200 day simple moving average is $2.40. Celularity has a one year low of $1.00 and a one year high of $7.97.

Celularity (NASDAQ:CELU) last released its quarterly earnings data on Friday, December 6th. The company reported ($0.73) EPS for the quarter. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. C V Starr & Co. Inc. bought a new stake in shares of Celularity in the fourth quarter worth about $1,589,000. Two Sigma Investments LP bought a new stake in Celularity in the fourth quarter valued at $93,000. Biltmore Family Office LLC purchased a new position in Celularity during the 4th quarter valued at $73,000. Finally, Keynote Financial Services LLC lifted its position in shares of Celularity by 90.1% in the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock worth $52,000 after purchasing an additional 11,863 shares during the period. Institutional investors own 19.02% of the company’s stock.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.